Ancilia Bio

Drug Discovery · New York, NY · Founded 2019 · Privately Held (backing)

Developer of virus-resistant live bacterial products designed to modulate the human microbiome. Ancilia Bio is based in New York, NY and was founded in 2019. It was valued at $28 million at its seed round in Apr 2026, the last priced event on record. It has raised $11.1 million across 1 recorded round; the latest was an early-stage round in Apr 2023.

PMV mark · valuation
$28.0M
Oct 2026
Priced at
its seed round
Apr 2026
Total raised
$11.1M
Last round
Early Stage VC
Apr 2023
What is Ancilia Bio worth?
$28.0MPrivateMarketView mark · Oct 2026

Valued at $28.0M at its seed round, Apr 2026. Nothing has traded since.

Free account
More of Ancilia Bio with a free account
  • ·The complete investor list: 13 names
  • ·Watch Ancilia Bio: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Valuation timeline

0 priced rounds · 32 daily marks since · Sep 2026 – Oct 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free account.Unlock the axis

Membership and data by Private Market View

Ancilia Bio funding history

1 rounds
DateRoundRaisedPost-money
Apr 2023Early Stage VC—▮
Unlock post-money valuations

Membership and data by Private Market View

Ancilia Bio valuation

Ancilia Bio was valued at $28 million at its seed round in Apr 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Ancilia Bio raised?

Ancilia Bio has raised $11.1 million in total; 1 of its rounds is on record. The most recent was an early-stage round in Apr 2023.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Persephone Biosciences ($37.3 million), Solarea Bio ($37 million) and PAhR Therapeutics ($25 million).

How Ancilia Bio's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Ancilia Bio, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by its last priced round. Question about this number? Full methodology →

Frequently asked about Ancilia Bio

What is Ancilia Bio worth?
Ancilia Bio is valued at $28.0M as of Oct 2026. Valued at $28.0M at its seed round, Apr 2026. Nothing has traded since.
How much has Ancilia Bio raised?
Ancilia Bio has raised $11.1M in total funding across 1 recorded rounds.
When did Ancilia Bio last raise?
Ancilia Bio last raised in Apr 2023 (Early Stage VC).